EGFR and non-small cell lung carcinoma: Recent studies showed that KRAS p.G12C mutation was detected in 1% of EGFR-positive NSCLC patients who progress with a first-line TKI [25], and last year the FDA approved sotorasib as the first inhibitor of KRAS in NSCLC that acts by blocking KRAS-G12C mutation [55].